Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP 90 Return-on-Tangible-Equity is 52.29% as of Mar. 2026, which is 52% above its 10-year median of 34.50. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 901 Drug Manufacturers companies, AFT Pharmaceuticals ranks better than 88.46% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AFT Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was A$19.1 Mil. AFT Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was A$36.4 Mil. Therefore, AFT Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 52.29%.
The historical rank and industry rank for AFT Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
ASX:AFP'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -132.92 Med: 34.5 Max: 176.28
Current: 35.59
During the past 11 years, AFT Pharmaceuticals's highest Return-on-Tangible-Equity was 176.28%. The lowest was -132.92%. And the median was 34.50%.
ASX:AFP's Return-on-Tangible-Equity is ranked better than 88.46% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs ASX:AFP: 35.59
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AFT Pharmaceuticals Return-on-Tangible-Equity Related Terms
AFT Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 52.29% mean?
AFT Pharmaceuticals (ASX:AFP) has a Return-on-Tangible-Equity of 52.29% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AFT Pharmaceuticals and its competitors. This is 52% above median its historical median of 34.50. According to the industry distribution chart, AFT Pharmaceuticals ranks #104 out of 901 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is AFT Pharmaceuticals' Return-on-Tangible-Equity too high?
AFT Pharmaceuticals' current Return-on-Tangible-Equity of 52.29% is 52% above median its 10-year median of 34.50. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. AFT Pharmaceuticals' value of 52.29% is 561.9% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #104 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #104 out of 901 companies for Return-on-Tangible-Equity. This places AFT Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. AFT Pharmaceuticals' value of 52.29% is 561.9% above this benchmark. While the company's 10-year median is 34.50 vs. the industry median of 7.90, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Return-on-Tangible-Equity of 52.29% is 561.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Return-on-Tangible-Equity is 52.29%, which is 52% above median its own 10-year median of 34.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Return-on-Tangible-Equity is 52.29%, which is 52% above median its 10-year median of 34.50 and 561.9% above the Drug Manufacturers industry median of 7.90. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Return-on-Tangible-Equity is 52.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Return-on-Tangible-Equity: 52.29% (52% above median its 10-year median of 34.50)
GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
Industry Position: 561.9% above the Drug Manufacturers median (#104 of 901)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score
Get the complete analysis for ASX:AFP
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
